TY - JOUR
T1 - High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma
AU - Alvino, Ester
AU - Passarelli, Francesca
AU - Cannavò, Elda
AU - Fortes, Cristina
AU - Mastroeni, Simona
AU - Caporali, Simona
AU - Jiricny, Josef
AU - Cappellini, Gian Carlo Antonini
AU - Scoppola, Alessandro
AU - Marchetti, Paolo
AU - Modesti, Andrea
AU - D'Atri, Stefania
PY - 2014
Y1 - 2014
N2 - Objectives: The outcome of patients with primary melanoma (PM) cannot be completely explained based on currently adopted clinical-histopathologic criteria. In this study, we evaluated the potential prognostic value of mismatch repair protein expression in PMs. Methods: We examined the immunohistochemical staining of mismatch repair proteins in 18 benign nevi and 101 stage I to III PMs and investigated their association with tumor clinicopathologic variables and melanoma mortality. Results: Expression of MSH2, MLH1, and PMS2 was high in benign nevi and reduced in a subset of PMs. Conversely, MSH6 expression was absent or extremely low in benign nevi and increased in a subset of PMs. In the multivariate analysis, including sex, age, Breslow thickness, and ulceration, high MSH6 expression in PMs (ie, immunostaining in >20% of tumor cells) was significantly associated with an increased risk of melanoma mortality (relative risk, 3.76; 95% confidence interval, 1.12-12.70). Conclusions: MSH6 protein expression can be a valuable marker to improve prognosis assessment in PMs.
AB - Objectives: The outcome of patients with primary melanoma (PM) cannot be completely explained based on currently adopted clinical-histopathologic criteria. In this study, we evaluated the potential prognostic value of mismatch repair protein expression in PMs. Methods: We examined the immunohistochemical staining of mismatch repair proteins in 18 benign nevi and 101 stage I to III PMs and investigated their association with tumor clinicopathologic variables and melanoma mortality. Results: Expression of MSH2, MLH1, and PMS2 was high in benign nevi and reduced in a subset of PMs. Conversely, MSH6 expression was absent or extremely low in benign nevi and increased in a subset of PMs. In the multivariate analysis, including sex, age, Breslow thickness, and ulceration, high MSH6 expression in PMs (ie, immunostaining in >20% of tumor cells) was significantly associated with an increased risk of melanoma mortality (relative risk, 3.76; 95% confidence interval, 1.12-12.70). Conclusions: MSH6 protein expression can be a valuable marker to improve prognosis assessment in PMs.
KW - Melanoma
KW - Mismatch repair
KW - MSH6
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84904545812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904545812&partnerID=8YFLogxK
U2 - 10.1309/AJCPCX2D9YULBBLG
DO - 10.1309/AJCPCX2D9YULBBLG
M3 - Article
C2 - 24926095
AN - SCOPUS:84904545812
VL - 142
SP - 121
EP - 132
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
SN - 0002-9173
IS - 1
ER -